- ISIN
- US37954Y4347
- CUSIP
- 37954Y434
- Issuer
- Global X
- Inception Date
- Apr 5, 2019
- Region
- North America (U.S.)
- Category
- Health & Biotech Equities
- Leveraged
- 1x (No leverage)
- Index Tracked
- Solactive Genomics Index
- Distribution Policy
- Distributing
- Asset Class
- Equity
- Asset Class Size
- Multi-Cap
- Asset Class Style
- Growth
- Assets Under Management
- $58M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
GNOM Performance Chart
Global X Genomics & Biotechnology ETF (GNOM) is up 5.1% since the beginning of the year. GNOM is currently trading at $48 per share. Investors who bought $1,000 worth of GNOM shares 5 years ago would now be looking at an investment worth $537.
Loading charts...
Returns By Period
Global X Genomics & Biotechnology ETF (GNOM) has returned 5.11% so far this year and 44.86% over the past 12 months.
Global X Genomics & Biotechnology ETF
- 1D
- -1.62%
- 1M
- 3.00%
- YTD
- 5.11%
- 6M
- 1.62%
- 1Y
- 44.86%
- 3Y*
- -1.47%
- 5Y*
- -11.69%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.30%
- 1M
- 0.09%
- YTD
- 8.18%
- 6M
- 8.17%
- 1Y
- 23.42%
- 3Y*
- 19.88%
- 5Y*
- 11.91%
- 10Y*
- 13.45%
GNOM Monthly Returns History
Based on dividend-adjusted daily data since Apr 10, 2019, GNOM's average daily return is +0.01%, while the average monthly return is +0.08%. At this rate, an investment would double in approximately 72.2 years.
Historically, 46% of months were positive and 54% were negative. The best month was Nov 2019 with a return of +18.5%, while the worst month was Jan 2022 at -18.7%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 9 months.
On a daily basis, GNOM closed higher 50% of trading days. The best single day was Apr 9, 2025 with a return of +9.8%, while the worst single day was Mar 12, 2020 at -11.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.91% | -0.05% | -8.22% | 3.65% | 9.58% | -3.83% | 5.11% | ||||||
| 2025 | 4.84% | -9.33% | -13.87% | 3.02% | -5.13% | 8.60% | 2.86% | 5.92% | 5.70% | 17.00% | 2.08% | -0.74% | 18.65% |
| 2024 | -6.99% | 11.44% | -5.01% | -13.44% | 3.05% | 2.86% | 11.40% | -2.15% | -1.14% | -7.73% | 4.43% | -10.42% | -15.99% |
| 2023 | 7.35% | -7.00% | -2.45% | -0.49% | -0.33% | -0.82% | 1.24% | -8.48% | -9.44% | -12.98% | 17.69% | 10.97% | -8.63% |
| 2022 | -18.69% | -4.21% | -2.78% | -15.24% | -5.81% | 1.83% | 16.53% | -2.88% | -9.26% | 4.78% | 2.66% | -6.30% | -36.27% |
| 2021 | 5.05% | -3.76% | -5.86% | 0.13% | -4.49% | 15.77% | -7.87% | 5.19% | -8.21% | -3.21% | -3.78% | -3.70% | -15.93% |
Benchmark Metrics
Global X Genomics & Biotechnology ETF has an annualized alpha of -13.08%, beta of 1.09, and R2 of 0.40 versus S&P 500 Index. Calculated based on daily prices since April 10, 2019.
- This ETF participated in 143.60% of S&P 500 Index downside but only 81.65% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.40 means the benchmark explains less than half of this ETF's behavior - treat beta with caution or consider switching to a more representative benchmark.
- Alpha
- -13.08%
- Beta
- 1.09
- R²
- 0.40
- Upside Capture
- 81.65%
- Downside Capture
- 143.60%
Expense Ratio
GNOM has an expense ratio of 0.50%, placing it in the medium range.
Return for Risk
Risk / Return Rank
GNOM ranks 53 for risk / return — on par with similar ETFs. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and compare them to S&P 500 Index.
| GNOM | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.26 | ||
| Sortino ratioReturn per unit of downside risk | -0.19 | ||
| Omega ratioGain probability vs. loss probability | 1.28 | 1.35 | -0.07 |
| Calmar ratioReturn relative to maximum drawdown | 2.48 | 2.59 | -0.11 |
| Martin ratioReturn relative to average drawdown | 7.12 | 11.84 | -4.73 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Global X Genomics & Biotechnology ETF provided a 1.31% dividend yield over the last twelve months, with an annual payout of $0.62 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Dividend | $0.62 | $0.62 | $0.00 | $0.00 | $0.00 | $0.03 | $0.13 |
Dividend yield | 1.31% | 1.37% | 0.00% | 0.00% | 0.00% | 0.03% | 0.14% |
Monthly Dividends
The table displays the monthly dividend distributions for Global X Genomics & Biotechnology ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.03 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.59 | $0.62 |
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.03 | $0.03 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Global X Genomics & Biotechnology ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Global X Genomics & Biotechnology ETF was 75.00%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Global X Genomics & Biotechnology ETF drawdown is 56.56%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -75.00%Apr 2025 | 4y 1mo | — | 5y 4moFeb 2021 - now |
COVID crash2020 | -35.36%Mar 2020 | 2mo 23d | 2mo 1d | 4mo 24dDec 2019 - May 2020 |
2019 bear market2019 | -21.60%Oct 2019 | 5mo 24d | 1mo 26d | 7mo 20dApr 2019 - Nov 2019 |
2020 correction2020 | -14.38%Sep 2020 | 1mo 19d | 29d | 2mo 18dJul 2020 - Oct 2020 |
2020 pullback2020 | -9.15%Oct 2020 | 16d | 12d | 28dOct 2020 - Nov 2020 |
Drawdown Indicators
| GNOM | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -75.00% | -56.78% | -18.22% |
Max Drawdown (1Y)Largest decline over 1 year | -18.17% | -9.10% | -9.07% |
Max Drawdown (3Y)Largest decline over 3 years | -46.47% | -18.90% | -27.57% |
Max Drawdown (5Y)Largest decline over 5 years | -72.29% | -25.43% | -46.86% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -56.56% | -2.68% | -53.88% |
Average DrawdownAverage peak-to-trough decline | -40.56% | -10.72% | -29.84% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.32% | 1.98% | +4.34% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Build a portfolio with GNOM
Add Global X Genomics & Biotechnology ETF to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with GNOM